Measuring Blood Vessel Density in the Optic Nerve of Multiple Sclerosis Patients With OCTA
Quantitative OCT Angiography Differences in Optic Nerve Vascular Density in Multiple Sclerosis: A Case-Control Study
The goal of this observational study is to learn about the effect of multiple sclerosis on the blood flow of the optic nerve of affected patients compared to normal subjects by OCTA. The main question it aims to answer is:
- Does MS change the blood flow in the optic nerve?
- If it does, can measuring this blood flow be used as a simple sign (a biomarker) to help doctors understand and manage MS?
We used a quick and painless eye scan called Optical Coherence Tomography Angiography (OCTA). This special scan takes detailed pictures of the blood vessels in the optic nerve without needing any injections. We performed this scan on two groups of people: one group with MS and one group without MS, and then compare the results.
In simple terms, why is this important? If we can show that MS affects the optic nerve blood vessels, it could give us a new, quick way to monitor the disease and see how it is progressing, just by doing a simple eye scan.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The optic nerve is like the main cable that carries visual information from the eye to the brain. In Multiple Sclerosis (MS), the body's immune system mistakenly attacks the protective covering (called myelin) around nerve fibers, including those in the optic nerve. This often causes a condition called optic neuritis, which can lead to vision loss.
While we know MS damages the nerve fibers, we are now trying to understand how it affects the blood vessels that supply oxygen and nutrients to the optic nerve. Are these blood vessels damaged as well? Does reduced blood flow contribute to the nerve damage?
2. The Technology We Are Using
This study uses a advanced, non-invasive imaging technology called Optical Coherence Tomography Angiography (OCTA).
What it does: The OCTA machine uses a safe, dim light beam to scan the optic nerve and macula. It works like a microscopic radar for blood vessels, allowing us to create very detailed, high-resolution 3D maps of the blood flow in the retina and optic nerve without any needles or injections.
What we measure: From these maps, we can quantitatively analyze the vessel density which is a percentage that tells us how much of a specific area is filled with functioning blood vessels. We will focus this measurement on the Radial Peripapillary Capillaries, which are the blood vessels that directly supply the optic nerve head.
3. The Purpose and Potential Impact of This Research
The main goal of this study is to determine if the blood vessel density in the optic nerve is a reliable biological marker (or biomarker) for MS.
A biomarker is an objective, measurable sign of a medical condition. If we can prove that changes in optic nerve blood flow are a consistent marker of MS, it could provide us with:
A new tool to help understand the disease activity in an individual.
A quick and painless way to potentially monitor how the disease is changing over time and whether treatments are effectively protecting the nervous system.
By comparing these detailed OCTA measurements between participants with and without MS, we hope to better understand the role of blood flow in the disease and contribute to improved future care for people living with MS.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Faiyum Governorate
-
Al Fayyum, Faiyum Governorate, Egitto, 63514
- Fayoum University hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- group 1; patients with multiple sclerosis with optic neuritis.
- group 2; normal healthy age matched controls
Exclusion Criteria:
- Other optic nerve diseases as glaucoma, papilledema or conginetal anomalies.
- Other macular diseases as AMD, CSR, scars …
- Errors of refraction outside +4 and -6 D range.
- Media opacity as cataracts or corneal opacities that may interfere with the quality of scans.
- Signal strength index less than 4\10.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Multiple Sclerosis (MS) Cohort
26 eyes of patients with clinically definite MS
|
optic nerve head analysis as regards the vessel density and retinal nerve fiber layer thickness and ganglion cell complex analysis as regards thickness and focal loss volume and global loss volume.
|
|
Healthy Control Cohort
28 eyes of age- and sex-matched normal subjects
|
optic nerve head analysis as regards the vessel density and retinal nerve fiber layer thickness and ganglion cell complex analysis as regards thickness and focal loss volume and global loss volume.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
vessel density of the optic nerve head and peripapillary region measured by OCTA
Lasso di tempo: Baseline
|
Difference in microvascular vessel density, as measured by Optical Coherence Tomography Angiography (OCTA), in the optic nerve head and peripapillary region between patients with Multiple Sclerosis and healthy controls.
Analysis will include the whole disc area, inside the disc, and individual quadrants.
|
Baseline
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
RNFL thickness
Lasso di tempo: Baseline
|
Retinal Nerve Fiber Layer (RNFL) thickness, measured in micrometers, for the superior and inferior hemispheres of the optic nerve head.
|
Baseline
|
|
GCC thickness
Lasso di tempo: Baseline
|
The thickness of the macular Ganglion Cell Complex (GCC) was measured in micrometers for the superior and inferior hemispheres.
These measurements were then analyzed by the device's proprietary software to calculate the Focal Loss Volume (FLV) and Global Loss Volume (GLV) indices.
|
Baseline
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- R687
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Sclerosi multipla
-
Sanko UniversityCompletatoMULTIPLE SCLEROSIS | BILANCIO | VALIDITÀ | AFFIDABILITÀTurchia (Türkiye)
Prove cliniche su Optical Coherence Tomography Angiography
-
Medical University of ViennaReclutamento